Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Galleri Catches Unscreened and Late-Stage Cancers, But Misses Most Stage I Tumors - Making It an Additive Layer After Regular Screening
Fishtown Medicine•8 min read
4.96 (124)

Galleri Catches Unscreened and Late-Stage Cancers, But Misses Most Stage I Tumors - Making It an Additive Layer After Regular Screening

Why it is an additive 1- to 2-year layer for unscreened cancers after we optimize your immune terrain and lock in regular screening.

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated November 7, 2026
On This Page
  • Why does proactive cancer prevention start with your immune terrain and regular screenings?
  • What does the Galleri blood test do well, and where does it fall short?
  • What did the 2026 NHS-Galleri and PATHFINDER 2 trials prove?
  • Why is Galleri strictly additive to regular screening and symptom checks?
  • How Fishtown Medicine Approaches Galleri (1-Year vs. 2-Year Cadence)
  • Common Questions
  • Is the Grail Galleri test FDA-approved or covered by insurance?
  • How accurate is Galleri at catching early vs. late cancer?
  • What did the 2026 NHS-Galleri and PATHFINDER 2 trials show?
  • Should I do Galleri every year or every two years?
  • Can a normal Galleri test replace my colonoscopy or mammogram?
  • Deep Questions
  • Why did the NHS-Galleri trial miss its Stage III-IV goal when Stage IV cancers fell?
  • What is the workup timeline if my Galleri test comes back positive?
  • Why does SYMPLIFY report a 75.5% positive predictive value when screening studies report 46 to 60%?
  • How does whole-body MRI (MRI-DWI) compare with Galleri as an additive layer?
  • ✦Key Takeaways
  • Related at Fishtown Medicine
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

The Grail Galleri test is a multi-cancer early detection (MCED) blood test that looks for DNA fragments shed by tumors across more than 50 cancer types, many of which have no routine screening test. In the 2026 PATHFINDER 2 (n = 32,007) and NHS-Galleri (n = 142,250) trials, Galleri showed 99.5 to 99.6% specificity, a 46 to 60% positive predictive value, and 91 to 93% accuracy in naming the organ of origin, while lowering Stage IV diagnoses by 14% overall (26% by Round 3) and cutting emergency cancer diagnoses by 21.3%. However, it misses 83% of Stage I cancers (16.8% Stage I sensitivity) and did not lower combined Stage III and IV diagnoses in NHS-Galleri (IRR 1.03) because many tumors were caught at Stage III instead of Stage I. At Fishtown Medicine, we treat Galleri as an additive layer: we optimize your immune and metabolic foundations and complete all regular screenings first, stay attentive to small symptoms, and consider Galleri every 1 to 2 years for proactive adults 50+ or those with cancer in their family story.

TL;DR: The Grail Galleri blood test checks a single blood draw for tumor DNA across dozens of cancers, including ovarian, pancreatic, liver, esophageal, and blood cancers that have no routine screening test.

  • What we hoped for vs. what the 2026 trials showed: We wanted to see strong Stage I and II detection. Instead, Galleri is very effective at catching Stage III and IV cancers (77 to 90%), while missing most tiny Stage I cancers (16.8% overall; 37% across 12 aggressive types).1,2 In the 142,250-person NHS-Galleri trial, Stage IV cancers dropped 14% (26% by year three) and emergency diagnoses fell 21.3%, while Stage III diagnoses rose to offset them (IRR 1.03).1
  • What a positive or negative result means (PATHFINDER 2, 2026): Specificity is 99.64%. When a signal fires, 6 in 10 are confirmed cancer (60.3% PPV) and 4 in 10 are false alarms that take a median of 70 days of targeted scans to rule out.3 A negative result still misses 60 to 70% of cancers appearing over the next year, so it never clears a new symptom.3,4
  • How we sequence it: First, we strengthen your immune and metabolic terrain (Vitamin D to 70 ng/mL, ferritin, fasting insulin, sleep) and complete all regular organ screenings. Then, for proactive adults 50+ or patients with cancer in their family story, we consider layering Galleri once a year (higher risk) or every 2 years (moderate risk) as an additive check.5

On a phone call last week, a patient whose mother and aunt had both faced cancer asked me whether spending $949 on the Galleri blood test meant she could breathe easy for the year. I shared what I tell every family in my practice: the big 2026 trial showed Galleri is not as strong at catching tiny Stage I and II tumors as we all hoped, while being very effective at catching Stage III and IV cancers that have no routine screening test. That means a normal blood draw never replaces building your immune terrain, staying on top of mammograms and colonoscopies, or checking a small new symptom right away.

How testing works here

Dr. Ash orders this the same way he orders everything else, as part of primary care, so it is not something you can buy from us by itself. A number with nobody to read it against the rest of your picture is how most people end up with a result sitting in a portal and no idea what to do next.

What that looks like from your side is straightforward. The lab or imaging center bills you directly, at their price, with nothing added by us. Dr. Ash sends the order, reads the result next to your history and your other labs, and turns it into a plan you leave with. If there is something specific you want measured, that is a good thing to say up front.

Tell Dr. Ash what you want to find out

Why does proactive cancer prevention start with your immune terrain and regular screenings?

Every human being makes mutated cells inside their body every day. A strong immune system spots and clears those mutated cells before they can grow into a tumor. When a mutated cell slips past immune checks and hides as normal tissue, it can keep dividing.

Before we talk about a pricey, non-FDA-approved blood test like Galleri (~$949 self-pay), we handle the foundations that shape your daily biology:

  1. Immune and metabolic terrain: High fasting insulin and belly fat feed dividing cells, while poor sleep, low Vitamin D (we target 70 ng/mL), and low iron reserves (ferritin) weaken immune defense.
  2. Regular organ screenings: Colonoscopy, mammography (or breast MRI / ultrasound), cervical HPV/Pap testing, PSA + multiparametric MRI, skin exams, and low-dose chest CT (for eligible smokers) either remove precancerous growths or catch tiny Stage I tumors before they shed DNA into your blood.

Galleri Catches Late-Stage and Unscreened Cancers, But Misses Most Stage I Tumors Figure: Across CCGA3, PATHFINDER 2 (n = 32,007), and the 142,250-adult NHS-Galleri trial, Galleri caught 77 to 90% of Stage III-IV cancers and cut Stage IV diagnoses by 14 to 26%, while missing 83% of Stage I tumors. In primary care, we optimize immune/metabolic foundations and routine organ screenings first before layering Galleri every 1 to 2 years.

What does the Galleri blood test do well, and where does it fall short?

Galleri is strong at flagging fast-growing, unscreened cancers once they shed DNA into the blood, and weak at catching small Stage I tumors that stay behind tissue barriers.1,2,3

About 70% of cancer deaths in the United States come from tumors that have no routine screening test at all. Those include ovarian, pancreatic, liver, bile duct, esophageal, stomach, head and neck, lymphoma, and myeloma. When Galleri flags a signal, its Cancer Signal Origin (CSO) prediction names the right organ 91 to 93% of the time.3,4 That lets us aim an MRI, CT, or scope straight at that organ. In the first PATHFINDER study, 74% of the cancers Galleri caught were types with no standard screening test.6

The trade-off is stage sensitivity. In the CCGA3 validation study (n = 4,077), detection rose sharply with tumor stage:2

  • Stage I: 16.8% across all cancers (37% across the 12 deadliest cancer types).
  • Stage II: 40.4% across all cancers (70% across the 12 deadliest types).
  • Stage III: 77.0% across all cancers (87% across the 12 deadliest types).
  • Stage IV: 90.1% across all cancers (93% across the 12 deadliest types).

In plain terms, the big trials showed that Galleri is not yet the Stage I and II detector we all wished for. It acts mainly as a Stage II, III, and IV net for cancers that have no other test.

What did the 2026 NHS-Galleri and PATHFINDER 2 trials prove?

In late 2026, two large trials gave us clear numbers on how Galleri performs in healthy adults over 50:1,3,4

Study & DesignWhat It Found When Positive (Specificity, PPV, CSO)What It Caught vs. Missed (Sensitivity & Stage Shift)Workup Timeline & Practical Meaning
PATHFINDER 2 (Nature Medicine Sept 2026, n = 32,007 adults >= 50)Specificity 99.64%; PPV 60.3% (up from 38 to 43% in PATHFINDER 1); CSO accuracy 91.3%.Caught 39.3% of all cancers appearing within 1 year (69.8% of the 12 lethal types); 53% of new cancers found were Stage I or II.Median 37 days to confirm cancer vs. 70 days to clear a false alarm (down from 162 days in PATHFINDER 1). Only 0.6% of all tested adults needed a biopsy or scope.
NHS-Galleri RCT (NEJM & Nature Medicine Oct 2026, n = 142,250, 3 annual draws)Specificity 99.5 to 99.6%; PPV 58.0% (Rd 1) -> 50.4% (Rd 2) -> 45.8% (Rd 3); CSO 91.1 to 93.6%.Primary Stage III + IV endpoint missed (IRR 1.03): fewer Stage IV cases (341 vs. 394, -14% overall, -26% in Round 3) were offset by more Stage III cases (360 vs. 287).Emergency hospital cancer diagnoses dropped 21.3%, while 12-month sensitivity ran 37.2% in Round 1 and ~27% in Rounds 2 and 3. Five-year survival data are still pending.
SYMPLIFY (Lancet Oncology 2023, n = 5,461 symptomatic referrals)Specificity 98.4%; PPV 75.5% (high because 6.7% of symptomatic patients already had cancer).Sensitivity 66.3% overall (Stage I still 24.2%).Tested people who already had red-flag symptoms; a negative test (2.4% false-negative rate) cannot be used to skip a symptom workup.7

Why is Galleri strictly additive to regular screening and symptom checks?

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can follow.

Start your intake

A "No Cancer Signal Detected" report barely changes your chance of having an early, slow-shedding cancer (negative likelihood ratio 0.61 in PATHFINDER 2). It can never replace your regular screenings or quiet a new symptom.3,5

In PATHFINDER 2, 61% of the cancers Galleri missed were breast, prostate, colon, lung, or cervical cancers that already have standard screening tests.3 Specifically, Galleri misses:

  • 97.4% of Stage I breast cancers (2.6% sensitivity) - mammography, breast MRI, and breast ultrasound catch these while they are still localized.2
  • 97.5% of melanomas (4 of 157 caught in NHS-Galleri) - a dermatologist's visual skin check catches these on the surface.4
  • About 90% of localized prostate cancers (9 to 11% sensitivity) - PSA density and multiparametric MRI catch these early.2,4
  • Precancerous colon polyps and cervical precancer (CIN) - colonoscopy and HPV/Pap testing prevent cancer by removing precancerous tissue before it turns malignant.

Just as important, it is 2026 and we still do not have a blood test that rules out early cancer when you feel something off. If you notice new bruising, a lump, a change in bowel habits, postmenopausal bleeding, or lasting pain, we check that symptom right away even if your Galleri test was normal last month.

How Fishtown Medicine Approaches Galleri (1-Year vs. 2-Year Cadence)

Instead of treating Galleri as either a miracle test or a useless one, we place it in a calm, four-part order:

  1. Optimize the terrain and finish regular screenings first: We dial in your Vitamin D (70 ng/mL), ferritin, fasting insulin, ApoB, and sleep. We also make sure your colonoscopy, breast imaging, cervical screen, prostate check, and skin exam are current.
  2. Match the cadence to your personal and family story: Once your foundations are set, if cancer runs in your story (for example, a parent or sibling with ovarian, breast, pancreatic, stomach, or blood cancer, even when BRCA or Lynch testing is negative) or you want an additive net for unscreened organs after age 50, we can put Galleri in your plan:
    • Higher-risk family or exposure stories: We consider it once a year.
    • Moderate-risk proactive adults (50+): We often space it to every 2 years.
  3. Quarterback any positive signal calmly: If a signal ever comes back positive, you are not left alone with a scary PDF. We use the 91%-accurate organ prediction to order the targeted MRI, CT, or scope needed and walk with you until it is resolved.
Dr. Ash
"Every one of us makes mutated cells inside our body every day, and a strong immune system spots and clears them. When cancer is part of our family story, we want to be much more proactive. There is a test called the Grail Galleri that is not FDA-approved and costs about $949 out of pocket. The major trial that came out on it showed it was not as effective as I would have wanted for Stage I and II detection, while being very effective at Stage III and IV - which means it is additive and never replaces your regular screenings. Once we have optimized your Vitamin D, iron, metabolic health, and regular screenings, I will often consider it once a year for higher-risk stories or every two years for others. My takeaway from the 2026 data is simple: we do our regular screenings, we can layer Galleri on top to stay ahead, and because it is still 2026 without a perfect tool, we stay super attentive to small symptoms."
✦

Key Takeaways

  1. Galleri supplements routine screening without replacing it: Keep colonoscopy, mammography, low-dose chest CT for eligible smokers, and cervical screening current because blood-based MCED testing is strictly an additive second layer.
  2. High specificity pairs with low Stage I sensitivity: Galleri carries roughly 99.5% specificity (0.4% to 0.5% false-alarm rate) and accurately points to tissue of origin, yet catches only 16.8% of Stage I cancers because tiny tumors shed minimal DNA.
  3. Clinical trials clarify predictive value and stage-shift limits: NHS-Galleri and PATHFINDER 2 data show positive predictive values near 43% to 62%, while long-term endpoints weigh whether earlier detection lowers overall cancer deaths.
  4. CADENCE matches testing cadence to personal risk: Low-risk adults under 50 skip MCED testing, whereas elevated-risk adults 50+ weigh annual or biennial draws with clear counseling on false-negative limits.

Related at Fishtown Medicine

  • What the NHS-Galleri Trial Showed - deeper dive into the 142,250-person NEJM randomized trial
  • Advanced Cancer Screening - how we layer immune foundations, regular screening, genetics, Galleri, and MRI-DWI
  • Preventing Heart Disease and Cancer Blueprint - our complete Tier 1 and Tier 2 prevention architecture
  • Full-Body MRI: What the Data Show - how radiation-free MRI-DWI compares with liquid biopsy
  • Your PSA Came Back High - the multiparametric MRI and PSA density pathway before prostate biopsy

Scientific References

  1. Sasieni P, Johnson P, Round T, et al. "Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis (NHS-Galleri)." The New England Journal of Medicine. 2026 Oct 8.
  2. Klein EA, Richards D, Cohn A, et al. "Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set (CCGA3)." Annals of Oncology. 2021;32(9):1167-1177.
  3. Nabavizadeh N, McDonnell C, Kurbegov D, et al. "Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study." Nature Medicine. 2026 Sep 22.
  4. Neal RD, Dolly S, Johnson P, et al. "Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial." Nature Medicine. 2026.
  5. Hoffman RM, Wolf AMD, Raoof S, et al. "Multicancer Early Detection Testing: Guidance for Primary Care Discussions With Patients." Cancer. 2025.
  6. Schrag D, Beer TM, McDonnell CH, et al. "Blood-Based Tests for Multicancer Early Detection (PATHFINDER): A Prospective Cohort Study." The Lancet. 2023;402(10409):1251-1260.
  7. Nicholson BD, Oke J, Virdee PS, et al. "Multi-Cancer Early Detection Test in Symptomatic Patients Referred for Cancer Investigation in England and Wales (SYMPLIFY)." The Lancet Oncology. 2023;24(7):733-743.
  8. Hunter DJ. "A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer." The New England Journal of Medicine. 2026 Oct 8.

Dr. Ash is a board-certified internal medicine physician at Fishtown Medicine in Philadelphia. He practices proactive, evidence-based primary care that combines metabolic and immune optimization with thoughtful cancer screening.

Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Diagnostics

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start Your Intake
Medical Disclaimer: This resource provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all" - the right plan must be matched to your unique lab work, family history, and goals. Consult Dr. Ash to determine if this approach is right for you, particularly if you have chronic health conditions or are taking prescription medications.

Frequently Asked Questions

Common Questions

Galleri is currently offered as a CLIA-certified laboratory-developed test (LDT) while the FDA reviews its premarket approval application (submitted in 2026). Because medical guidelines do not yet endorse multi-cancer blood tests for routine population screening, insurance and Medicare do not cover it, and the test runs about $949 out of pocket.
Galleri is very specific (99.5 to 99.6%, meaning fewer than 1 in 200 healthy people get a false alarm) and catches 77% of Stage III and 90% of Stage IV cancers. Its main limit is early disease: in validation testing it caught only 16.8% of Stage I cancers overall (and 37% of Stage I cases across the 12 deadliest cancers), because tiny early tumors shed very little DNA into the blood.
In the 142,250-person NHS-Galleri randomized trial (NEJM October 2026), three annual Galleri draws did not lower the combined total of Stage III and IV cancers (IRR 1.03) because fewer Stage IV diagnoses (down 14% overall, 26% in Round 3) were offset by more cancers caught at Stage III, while emergency cancer diagnoses fell 21.3%. In the 32,007-person PATHFINDER 2 study (Nature Medicine September 2026), positive predictive value rose to 60.3% and organ-of-origin accuracy reached 91.3%.
At Fishtown Medicine, after we optimize your metabolic and immune foundations and complete all standard organ screenings, Dr. Ash matches the schedule to your risk: typically once a year for adults with a strong family history of cancer (such as ovarian, pancreatic, breast, or GI tumors) and every two years for moderate-risk proactive adults over 50.
No. Galleri is strictly additive and never replaces regular screening. It misses 97.4% of Stage I breast cancers, 97.5% of melanomas, and roughly 90% of localized prostate cancers, and it cannot detect precancerous colon polyps or cervical precancer. A normal result also never rules out a new symptom.

Deep-Dive Questions

The NHS-Galleri trial was designed around a combined Stage III plus Stage IV primary endpoint. Because cell-free DNA shedding rises sharply once a tumor reaches Stage III (77% sensitivity vs. 16.8% in Stage I), the test caught many hidden tumors at Stage III that would otherwise have surfaced later at Stage IV. That shifted cases from Stage IV (341 vs. 394) into Stage III (360 vs. 287), leaving the combined Stage III + IV count flat until 5-year mortality data show whether catching those tumors at Stage III saves lives.
In the 2026 PATHFINDER 2 study of 32,007 adults using the updated Galleri assay, 60.3% of positive signals were confirmed to be cancer and 39.7% were false alarms. Because the test's Cancer Signal Origin (CSO) prediction named the right organ 91.3% of the time, confirming a cancer took a median of 37 days, and ruling out a false alarm took a median of 70 days (down from 162 days in the original PATHFINDER 1 study). Only 0.6% of all tested adults needed an invasive biopsy or scope.
The SYMPLIFY study (Lancet Oncology 2023) tested patients who were already referred urgently for red-flag cancer symptoms, where 6.7% of the group had cancer. When you test healthy people without symptoms (where 1-year cancer prevalence is closer to 1 to 1.5%), positive predictive value is between 46 and 60%. Even in symptomatic patients, Stage I sensitivity was only 24.2%, which is why a negative blood test never stops us from investigating a symptom.
Both are optional second-layer tools used only after standard screenings are current, and each has a different blind spot. Galleri is a blood draw with a very low false-alarm rate (0.4 to 0.5%) that covers blood cancers and high-shedding organ tumors, but misses most Stage I disease. Whole-body MRI with diffusion-weighted imaging (MRI-DWI) can spot small Stage I organ tumors in the kidney, liver, or pancreas without radiation, but turns up benign incidental spots in roughly 30% of scans and cannot see blood cancers or colon polyps.

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

Early Cancer Detection and Whole Body MRI Philadelphia | Medicine 3.0

Early Cancer Detection and Whole Body MRI Philadelphia | Medicine 3.0

Go beyond standard cancer screening. A Philadelphia primary care practice using liquid biopsies and whole-body MRI to find disease earlier.

Read Deep Dive
Genetics: The Dial You Can Turn

Genetics: The Dial You Can Turn

How we use genetic data at Fishtown Medicine. Which tests change the plan, which ones are expensive curiosity, and why your DNA shapes your risk rather than determining it.

Read Deep Dive
ApoB vs LDL: Why Your "Normal" Cholesterol Score Might Be Misleading

ApoB vs LDL: Why Your "Normal" Cholesterol Score Might Be Misleading

A guide to ApoB vs LDL and why a normal cholesterol report can still hide serious heart risk. From a Medicine 3.0 practice in Philadelphia.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

If anything you read here raised a question, share it in your own words. Dr. Ash reads every intake personally, and you can text or email us anytime.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs